Companies › Peptomyc
1 active drug program in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| OMO-103 Myc inhibitor | MYC | Phase 1 | Metastatic Pancreatic Cancer; Osteosarcoma | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06059001 | OMO-103 | Phase 1 | Metastatic Pancreatic Cancer | Oncology | May 2026 |
| NCT06650514 | OMO-103 | Phase 2 | Osteosarcoma | Oncology | Dec 2026 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.